Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
 |
|||||||||
March 11, 2025 – TheNewswire – Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce an upcoming poster presentation highlighting the effects of Tumour Defence Breaker™, L-DOS47, in CEACAM6-expressing head and neck cancer cells and colon adenocarcinoma cells in tumor-bearing mice at the 20th European Molecular Imaging Meeting (“EMIM 2025”) taking place 11–14 March in Bilbao, Spain.
The study demonstrated that L-DOS47 effectively neutralizes the acidic tumor microenvironment (TME) in new CEACAM6-expressing solid tumors, a critical factor in tumor progression and immune evasion. In head and neck cancer and colon adenocarcinoma models, treatment with L-DOS47 raised tumor pH levels within 24 hours with a transient but measurable effect lasting up to 48 hours, effectively neutralizing acidity that fuels tumor growth. MRI scans and tissue analysis also revealed signs of tumor necrosis, underscoring L-DOS47’s impact on tumor viability. Importantly, the study confirmed that L-DOS47 precisely targets CEACAM6-expressing tumors while being safely cleared from the body. These results add to the growing evidence that L-DOS47 is a powerful Tumour Defence Breaker™, shifting the tumor microenvironment to make prevalent, hard-to-treat cancers more vulnerable to treatment. The abstract and poster are publicly available on EMIM 2025’s Event Class via the following link: https://www.eventclass.it/emim2025/scientific/online-program/poster-session?s=PO+01
Poster details:
Title: Paradigm Change in Oncoimmunology: Tumor antigen specific normalization of the extracellular pH in the tumor microenvironment of solid tumors by L-DOS47.
Session: Poster Session I
Presentation date: Wednesday, 12 March 2025
Abstract Number: ONCO-011
Presenters: Dimitri Stowbur, PhD, Postdoctoral Reasearch Fellow in Cancer Immunotherapy and Modulation of the Tumor Microenvironment, and Csaba Toemboely, PhD, Senior Researcher in Imaging probe development and cancer immunotherapy at the University of Tuebingen.
About the European Molecular Imaging Meeting (EMIM) Annual Meeting
The European Molecular Imaging Meeting (EMIM) is a leading international conference dedicated to advancing molecular imaging and its applications in biomedical research. Organized by the European Society for Molecular Imaging (ESMI), the 20th EMIM brings together over 1,100 scientists, clinicians, and industry experts to explore the latest breakthroughs in imaging technologies, biomarkers, and translational research. The 2025 meeting will take place in Bilbao, Spain, from March 11–14, providing a platform for cutting-edge presentations, collaborative discussions, and emerging innovations that drive the future of molecular imaging. For more information, visit: https://e-smi.eu/.
About Helix BioPharma
Helix BioPharma Corp. is an oncology company shaping a near future where today’s hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The Company innovates from strength to tackle cancer’s biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing solid tumors. Its lead candidate, Tumour Defence BreakerTM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumors, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today’s front-running anti-cancer therapies. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery.
Helix is listed on the TSX under the symbol “HBP”, on OTC PINK under the symbol “HBPCD” and on FWB under the symbol “HBP0”. For more information, please visit: https://www.helixbiopharma.com/
For more information, please contact:
Helix BioPharma Corp.
Bay Adelaide Centre – North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: 604-428-7050
Jacek Antas, Director
Forward-Looking Statements and Risks and Uncertainties
This news release contains certain statements regarding Helix BioPharma Corp. that constitute forward-looking statements and information (collectively, “forward looking statements”) as defined by Canadian securities laws. Forward-looking statements include and are not limited to financial projections and expectations regarding Helix’s future business and operations, particularly related to the Company’s CEACAM6 platform, DOS47 and new asset transactions that Helix intends to close. These statements use terms like “estimates,” “expects,” “will,” and similar language indicating future events, or the negative thereof or any other comparable terminology referring to future events or results.
However, forward-looking statements are subject to risks and uncertainties beyond Helix’s control, which may lead to actual results differing materially from those anticipated. These risks and uncertainties include, but are not limited to, risks relating to Helix’s financial condition, including (a) lack of significant revenues to date and reliance on equity and other financing; (b) business, including its stage of development, government regulation, development success of and market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Helix to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Forward-looking statements reflect the management’s current beliefs and are based on information available to the management on the date of this news release, and the Company does not assume the obligation to update any forward-looking statement should those beliefs change, except as required by law. Further information regarding these risks and uncertainties can be found in Helix’s periodic reports and information forms on the Company’s SEDAR+ profile at www.sedarplus.ca.
_________________
Copyright (c) 2025 TheNewswire – All rights reserved.
